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ER = estrogen receptor; FISH = fluorescent in situ hybridization; LOH = loss of heterozygosity; NAF = nipple aspirate fluid; QM-MSP = quantitative
multiplex, methylation-specific polymerase chain reaction; PCR = polymerase chain reaction.
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Abstract
Intraductal approaches encompass procedures and technologies
that are designed to access and interrogate the ductal–alveolar
systems of the human breast, and include nipple aspiration, ductal
lavage, random periareolar fine needle aspiration, and ductoscopy.
These approaches are being used to collect and analyze fluids and
cells to develop methods for breast cancer detection and risk
assessment; to introduce imaging technologies to explore the
mammary tree for abnormalities; to administer therapeutic and/or
preventive agents directly to the breast tissue; and to explore the
biology of the normal mammary gland. The latest research findings
in these areas, presented at The 4th International Symposium on
the Intraductal Approach to Breast Cancer in 2005, are
summarized in this report.
Introduction
The human breast is composed of multiple ductal
lobular–alveolar systems that open onto the surface of the
nipple. Most breast cancers are thought to arise from the
epithelial cells lining the ductal–lobular junctions of these
structures. For many years a small group of investigators
pioneered methods to collect fluids and exfoliated cells from
the breast ducts by applying suction (nipple aspiration) to the
openings, and exfoliative cytology revealed that breast
cancer-associated abnormalities could be detected in these
samples [1-6]. Although this early ‘intraductal approach’
constituted a novel, noninvasive method for accessing the
mammary gland and presented opportunities for developing
new approaches for early breast cancer detection, the
approach remained under-explored for many decades.
In 1999, the First Symposium for Intraductal Approaches to
the Breast, attended by 30 investigators, was convened to
jumpstart a new wave of research in the field. Since then new
technologies have been developed to enhance the volume
and representation of collected fluids, and to facilitate the
introduction of therapeutic agents directly into the glandular
lumina. Intraductal fluids and cells have been evaluated by a
wide variety of genetic, epigenetic, and proteomic analyses,
providing new insights into the biology of the normal and
diseased breast. The 4th International Symposium on the
Intraductal Approach to Breast Cancer, hosted by the Dr
Susan Love Breast Cancer Research Foundation and held in
Santa Barbara, California on 10-13 March 2005, provided a
forum for the exchange and evaluation of these cumulative
research findings. Over 100 delegates attended the meeting,
including clinicians, basic scientists, translational investi-
gators, and breast cancer advocates. The program included
talks by 39 invited speakers and 11 pilot grant presenters in
sessions covering the evaluation of intraductal approaches
for breast cancer detection, risk assessment, intraductal
therapies, and investigating normal breast biology.
Nipple aspiration fluid: lessons learned and
questions raised
Several presentations reviewed and updated information from
earlier nipple aspiration fluid (NAF) studies. Nicholas Petrakis
(University of California, San Francisco, CA, USA)
summarized his extensive body of research on breast fluids,
showing that NAF production is associated with a
constellation of factors, including age, race, menopausal
status, and diet [2]. He also reviewed work performed in
collaboration with Margaret Wrensch (University of California,
San Francisco, CA, USA) that showed that the production
and cytologic properties of NAF are associated with breast
cancer risk [5,7]. Long-term follow up of women undergoing
nipple aspiration revealed that the risk for developing breast
cancer was two to five times greater for women diagnosed
with cytologic atypia relative to those who did not yield any
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fluid. In these studies, women who yielded acellular fluid or
fluid with normal cells were also at increased risk relative to
nonyielders, leading Dr Petrakis to conclude that, ‘yielding
fluid is a precursor of something going on in the breast.’
Gertrude Buehring (University of California, Berkeley, CA,
USA) presented the 20-year follow up of her prospective
observational cohort including 1605 asymptomatic women
who donated NAF between 1973 and 1976. Although the
study found no elevated risk among women who had acellular
fluid, there was a significant relative risk of 1.57 for women
who had fluid with epithelial cells. For premenopausal
women, the relative risk was 2.1. Based on these findings, Dr
Buehring concluded that, ‘NAF epithelial cells may be a
general indicator of breast pathology and their presence is
associated with a subsequent increase in breast cancer risk.’
Although these data confirm that NAF-yielding women have a
higher subsequent risk for developing breast cancer, it has
never been confirmed that NAF-yielding ducts are the ducts
at highest risk. In 1999 a microcatheter device was
developed to cannulate and lavage individual ductal systems
(ductal lavage) for the purpose of collecting higher numbers
of cells from the terminal regions of the mammary tree [8].
Nipple aspiration has been used in conjunction with ductal
lavage for the purpose of selecting ducts for cannulation.
Susan Love (Dr Susan Love Breast Cancer Research
Foundation, Pacific Palisades, CA, USA) framed two
assumptions upon which this practice has been based: NAF-
producing ducts are the most likely to be abnormal; and in
cancerous breasts the ducts with cancer will yield NAF with
malignant cells, whereas the other ducts will yield NAF with
atypia. However, recent findings have called these
assumptions into question. Two ductal lavage studies in
which nonproductive ducts were cannulated [9,10] have
revealed the presence of atypia in dry ducts, and Carol
Fabian’s group (University of Kansas, Kansas City, KS, USA)
demonstrated cytologic atypia by random periareolar fine
needle aspiration in 16% of women who did not express NAF
[11]. In addition, the selective cannulation of only the NAF-
yielding ducts in ductal lavage studies performed in women
with cancer and ductal carcinoma in situ has been
associated with low sensitivity for detecting cancer [12-14].
These findings suggest that the hypothesis that NAF-
producing ducts are more likely to be abnormal needs to be
revisited, and two of the presentations addressed this issue.
David Euhus (University of Texas Southwestern Medical
Center, Dallas, TX, USA) described the results of his ductal
lavage study conducted in 125 women [10]. All of the
women’s NAF-producing ducts were cannulated; in addition,
cannulation of at least one dry duct was attempted per
woman. Eighty per cent of the patients expressed NAF, and
on average three ducts per patient were lavaged. Dr Euhus
found that the cytologic atypia rate was identical for NAF-
producing ducts and dry ducts, and that the atypia rate was
similar for women who had high and low Gail scores. In
addition, atypia declined as women aged. Based on these
findings Dr Euhus concluded that, ‘NAF production is not
associated with lavage atypia’ and ‘five-year Gail risk over 1.7
percent does not predict lavage atypia.’
Susan Love reported initial findings from her foundation’s
Normal Breast Study. To date, 127 wet (NAF-producing) and
dry ducts have been lavaged in 31 women who are not at high
risk for breast cancer, and the fluids were analyzed for the
presence of protein and cells. Fifty per cent of the NAF-
producing ducts contained protein, as did 56% of the dry
ducts. Epithelial cells were found in 38% of the NAF-yielding
ducts and 27% of the dry ducts. These results raise questions
about what is being lavaged, and underscore the need to
correlate ductal anatomy and physiology. Collectively, the
paradoxical findings of these NAF studies generate questions
about the biological significance of breast fluid and its relation-
ship to cellularity, cytologic atypia, and breast cancer risk.
Clinical utility of ductal lavage and mammary
ductoscopy
Several presentations highlighted the current status of the
clinical applications of ductal lavage and mammary
ductoscopy in the diagnosis and treatment of breast
diseases. Seema Khan (Northwestern University School of
Medicine, Chicago, IL, USA) presented data in which ductal
lavage was performed on women with breast cancer
immediately prior to therapeutic or prophylactic mastectomy
to determine the diagnostic accuracy of the lavage results
[13]. Any duct that yielded NAF was lavaged and no direct
attempt was made to lavage the ducts with cancer. In 50% of
cases, the cancer-containing ducts did not yield NAF, and the
sensitivity of ductal lavage in confirming carcinoma based on
routine cytopathology was approximately 20%. Similar data
presented by Edi Brogi (Memorial Sloan-Kettering Cancer
Center, New York, NY, USA) confirmed a low sensitivity of
ductal lavage in predicting the presence of known cancer,
even in mastectomy specimens in which intraductal dye
injection confirmed that the cancer-containing duct was
being lavaged [12]. These studies reveal the limitations of
using ductal lavage for screening, and the presenters
concluded that those patients who are currently undergoing
ductal lavage must be followed carefully by routine imaging
methods even in the absence of atypical cytology.
With respect to current usage of ductal lavage in the clinic,
Freya Schnabel (Columbia Presbyterian Medical Center, New
York, NY, USA) and Gillian Mitchell (Peter MacCallum
Cancer Center, Melbourne, Australia) presented data that
highlighted high-risk patient decision making based on a
multimodal approach using ductal lavage in combination with
genetic testing and surveillance magnetic resonance imaging.
Allison Kurian (Stanford University Medical School, Palo Alto,
CA, USA) presented preliminary data on magnetic resonance
imaging galactography that suggested that ductal lavage of200
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two to three ductal systems could encompass approximately
30–50% of the breast ductal system. Katherine Lee
(Cleveland Clinic Foundation, Cleveland, OH, USA) reported
results on the use of ductal lavage in African-American
patients with known breast cancer that demonstrated
significant rates of atypia in the ipsilateral breast, suggesting
that ductal lavage may be of some use in identifying high-risk
African-American women who are not identified based upon
the Gail model index alone. Finally, Jeff Tice (University of
California, San Francisco, CA, USA) presented interesting
data analyzing a cohort of over 6900 asymptomatic women
with over 14 years follow up that suggested that NAF cytology
may increase the predictive value of the Gail model [15].
Shahla Masood (University of Health Sciences, Jacksonville,
FL, USA) summarized the challenges associated with breast
fluid cytomorphology and reviewed its utility for breast cancer
risk prediction in fine needle aspirate biopsies, NAF, and
ductal lavage. Although she concluded that it is possible to
use cytomorphology as a risk predictor, she emphasized that
there is no current consensus on how cytology should be
used in clinical practice, and underscored the need to further
develop criteria to define prognostically relevant atypia in
ductal lavage samples.
Mammary ductoscopy has been utilized in the intraoperative
setting in patients with both benign and malignant breast
conditions. William Dooley (University of Oklahoma Breast
Institute, Oklahoma City, OK, USA) updated his large
personal experience of using routine operative breast
endoscopy with an emphasis on patients undergoing breast-
conserving lumpectomy for cancer [16]. He reported that
more than 40% of patients undergoing lumpectomy for
breast cancer were found to have proliferative changes
(including atypical ductal hyperplasia) identified by
ductoscopy, which were located more than 1 cm away from
the primary breast tumor and outside of the standard
lumpectomy resection cavity. Based on the resection of these
proliferative lesions identified by ductoscopy, the annual
hazard rate for local failure has been reduced from 0.67% to
0.08%. Julian Kim (Cleveland Clinic Foundation, Cleveland,
OH, USA) presented data from a similar trial in which the
added value of ductoscopy-directed tissue resection was
evaluated in patients undergoing standard lumpectomy for
breast cancer. By contrast, although mammary ductoscopy
did visualize the primary tumor and proliferative lesions in
approximately 70% of the patients, many of these visualized
abnormalities were within the standard lumpectomy resection
cavity and thus offered no added benefit. Dr Kim also
presented data comparing mammary ductoscopy and
microductectomy with standard major duct excision in
patients who present with pathologic nipple discharge, which
suggested that microductectomy may identify fewer occult
cancers due to the limited tissue sampling as compared with
major duct excision. Two additional presentations by Volker
Jacobs (University Munich, Munich, Germany) and
Mohammed Keshtgar (University College London, London,
UK) outlined novel methods for enhancing the diagnostic
accuracy of mammary ductoscopy by either real-time auto-
fluorescence or optical interrogation of ductal tissue, which
are currently being translated from the preclinical to early
clinical stages.
The controversies surrounding the current clinical use of
ductal lavage and mammary ductoscopy were debated by
Seema Khan, Victor Vogel (University of Pittsburgh Medical
School, Pittsburgh, PA, USA), William Dooley, and Julian Kim.
Arguments for the use of ductal lavage included the strong
evidence that atypical ductal hyperplasia is correlated with an
elevated risk for breast cancer development, and those
patients diagnosed with atypia by ductal lavage do have the
opportunity to consider preventive measures. An opposing
viewpoint was presented that contends that, because of the
low sensitivity and specificity of ductal lavage, the procedure
is not accurate in identifying high-risk patients based on
cytology alone and may carry significant risk for false-negative
findings. The debate surrounding mammary ductoscopy
revolved around whether proliferative lesions, including
atypical ductal hyperplasia, identified by mammary
ductoscopy during breast-conserving lumpectomy for primary
breast cancer are clinically useful markers of risk for
locoregional recurrence or should be included in the surgical
resection specimen. Most of the panel members agreed that
well designed clinical trials with appropriate follow up will be
necessary to shed light on these areas of controversy.
Breast fluid biomarkers
The sensitivity of intraductal approaches to detect or predict
breast cancer is a compound measurement that reflects both
the sampling and analysis of fluids. Although cytology has
been used as the ‘gold standard’ in early studies to evaluate
breast fluids for risk assessment and cancer detection, it has
been proven to have low sensitivity for detecting malignancy
and reveals a high degree of prognostically ambiguous atypia.
In an effort to address these issues, the analysis of breast
fluids has been extended to a large variety of biomarkers.
Some investigators have taken an in situ approach in order to
colocalize markers and cytology to the same cells. Savitri
Krishmanurthy (MD Anderson Cancer Center, Houston, TX,
USA) described the use of interphase fluorescent in situ
hybridization (FISH) to measure chromosomal aneusomy on
previously Pap-stained NAF cytology specimens [17]. In
previous studies she detected aneusomy in all of the
cytologically malignant but only a subset of the cytologically
atypical samples. She discussed the potential utility of FISH
as an adjunct for confirming benign and malignant cytologic
findings, and for further stratifying the classification of
cytologic atypia. In a similar strategy to preserve cyto-
morphologic analysis, JianYu Rao (UCLA, Los Angeles, CA,
USA) used quantitative fluorescence image analysis to
analyze markers in ductal lavage thin prep specimens.201
Measurement of DNA 5cER (exceeding rate) content and G-
actin overexpression in a small validation study resulted in
100% sensitivity and 100% specificity, suggesting that
biomarker analysis may have better potential for separating
cancer and noncancer samples than cytology.
Breast fluid specimens typically contain large numbers of
infiltrating cells as well as benign epithelial cells, creating a
‘needle in a haystack’ challenge for biomarker development.
Methylation-specific PCR is particularly well suited to this
task because of its ability to detect rare cells containing
cancer-associated DNA methylation events [18,19]. Sara
Sukumar (Johns Hopkins University, Baltimore, MD, USA),
who pioneered the application of these assays to ductal
fluids, reported on her latest work to transition this approach
from a subjective, gel-based method into an objective,
automated, quantitative assay, termed QM-MSP (quantitative
multiplex methylation-specific PCR). This approach combines
the power of multiplex and real-time PCR to detect
methylation events simultaneously at multiple loci, and
increases the sensitivity of the approach to 1 in 104–107
copies of DNA [20]. In a pilot study with Savitri Krishnamurthy
and Henry Kuerer (MD Anderson Cancer Center, Houston,
TX, USA), QM-MSP analysis was applied to Pap-stained NAF
cytology slide cell scrapings. Analyzing a panel of 10 loci,
methylated alleles were detected in all of the malignant, a
subset of the atypical, and none of the normal samples. Dr
Sukumar is currently working to apply QM-MSP to breast
fluids collected by NAF, ductal lavage, and fine needle
aspiration, as well as plasma.
Edward Sauter (University of Missouri, Columbus, MO, USA)
also described the application of hypermethylation assays to
DNAs extracted from 22 matched pairs of NAF and breast
tumor tissue samples collected from breast cancer patients
[19]. Using a panel of six loci, he detected hypermethylation
in all of the malignant tissues and identical methylation
patterns in 82% of the matched NAF specimens. No
hypermethylation was detected in the normal tissues. He also
used a panel of 11 microsatellite markers to evaluate
matched specimens for loss of heterozygosity (LOH), and
microsatellite instability [21]. Identical alterations were
identified in 43% of fluids from matched cancer tissues
harboring changes. Luciane Cavalli (Georgetown University,
Washington, DC, USA), working to develop early detection
strategies for BRCA1 mutation carriers, reported on the
development of protocols to isolate free DNA from the
acellular fraction of ductal lavage fluids for molecular
evaluation, an approach that leaves the cellular fraction intact
for cytologic analysis [22]. Using PCR-based approaches on
these DNAs, she demonstrated LOH at the BRCA1 locus in
four out of nine known BRCA1 mutation carriers. Gillian
Mitchell and Imogen Locke (The Royal Marsden NHS
Foundation Trust, London, UK) also reported detection of
LOH at the BRCA1 and BRCA2 loci in ductal lavage fluids
from BRCA-positive women. Finally, Sauter and Cavelli also
described the detection of DNA mutations in mitochondrial
DNA extracted from breast fluids – an advantageous
approach because of the relative abundance of mitochondrial
versus nuclear DNA [22,23].
There were also two presentations describing the application
of SELDI-TOF/MS (surface-enhanced laser desorption and
ionization–time of flight/mass spectrometry) to nipple aspirate
fluids. Timothy Pawlik (MD Anderson Cancer Center,
Houston, TX, USA) analyzed the proteomic profiles of fluids
collected from the diseased and contralateral breasts of 23
breast cancer patients, and compared these with the profiles
of fluids collected from 10 healthy control inidividuals [24].
Significant differences in the profiles between the fluids
collected from patients and control inidividuals were
detected, but interestingly the proteomic profiles of the
cancerous and contralateral breast fluids of breast cancer
patients were highly conserved. Sascha Dua (Royal Marsden
Hospital Foundation Trust, London, UK) reported on her
experience to date with a small pilot set of nipple aspirate
fluids. In keeping with the observations presented by Pawlik,
they also identified differentially expressed peaks between
cancer and control fluids, but no significant differences
between fluids from the healthy and cancerous breasts of the
same patient. Both groups are working on identifing the
protein peaks and will follow up with validation studies.
Seema Khan summarized a body of work describing the
pathophysiology of the estrogen receptor (ER) in the human
breast, exploring its potential significance as a marker of
proliferation, and is currently performing studies to evaluate ER
in breast fluid cells. Highlighting the potential use of intraductal
approaches in chemoprevention trials, Arun Banu (MD
Anderson Cancer Center, Houston, TX, USA) summarized
preliminary results from a phase II prevention trial designed to
test whether celecoxib induces changes in proliferation and
apoptosis in the breast tissue of high-risk women. Using fine
needle aspiration and ductal lavage samples, she observed
significant downregulation of ER expression within 6 months of
treatment. She is also in the process of analyzing other markers
of proliferation and apoptosis.
Collectively, these studies demonstrate the successful
application of biomarkers to detect breast cancer associated
genetic, epigenetic, and proteomic abnormalities in breast
fluids collected by a variety of intraductal techniques. In
keeping with a growing body of published studies, markers
appear to have superior sensitivity for breast cancer detection
compared with cytology [14,17-23,25]. Ed Sauter concluded
his talk with the comment that no single marker has adequate
sensitivity to detect all malignancies, and an important goal
will be to create systematically a panel of markers with high
sensitivity and specificity. The successful evaluation and
validation of breast cancer detection biomarkers in breast
fluids will require the accurate sampling of ducts associated
with lesions.
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Spotlight on the future: intraductal therapy
The session that highlighted intraductal therapy approaches
demonstrated the rapid translation of preclinical testing to
early phase human clinical trials. Sara Sukumar presented
compelling data in a murine model of HER2/transgenic mice
demonstrating that intraductal administration of pegylated
liposomal doxorubicin (Doxil®, ALZA Corporation, Mountain
View, CA, USA) into mammary ducts prevented the formation
of mammary tumors and resulted in equivalent or superior
antitumor effects in a therapy model against established
tumors with less systemic toxicity as compared with
intravenous administration. Robert Goulet Jr (Indiana
University Medical Center, Indianapolis, IN, USA) presented
pilot study data on the feasibility of mammary intraductal
administration of either nanoparticles or Doxil in breasts
removed by mastectomy. In a majority of patients infused with
nanoparticles, the particles were confirmed to traverse into
the terminal lobules by fluorescence microscopy. M Ellen
Mahoney (Arcata, CA, USA) presented the first in vivo use of
intraductal Doxil describing a safety pilot in a woman two
months prior to a planned prophylactic mastectomy. The
procedure was done under local anesthesia with no acute
toxicity. Several new concept protocols were discussed at
the end of the session, which highlighted pilot studies of
intraductal delivery of either liposome or nanoparticle-
associated cytotoxic agents in patients with breast cancer.
Window on mammary gland biology
In his introductory remarks, Nick Petrakis (UCSF School of
Medicine, San Francisco, CA, USA) referred to breast fluids
as, “a ‘stew’ containing exfoliated epithelial cells, foam cells,
lymphocytes, disintegrating cellular debris, milk proteins, fat
globules, fatty acids, enzymes, immunoglobulins, and other
chemical substances derived from endogenous and
exogenous sources”. As such, ductal fluids reflect the
microenvironment of the breast and constitute a surrogate
with which to study the biology of the human mammary gland.
One of the key insights to emerge from intraductal studies is
the degree to which the mammary gland is infiltrated by
systemic cells. In fact, the most frequently observed cell type
in breast fluids has consistently been the mammary foam cell,
the origin of which has been debated as epithelial versus
macrophage for years. Sanford Barsky (Ohio State University,
Columbus, OH, USA) presented elegant data from a
transgenic mouse model in which labeled male bone marrow
cells were transplanted into irradiated female recipients.
Following the induction of psuedopregnancy to promote
mammary gland development, labeled macrophages were
observed in the mammary gland lumina. In another approach,
he used interphase FISH to show the presence of Y
chromosomes in breast tumor tissue macrophages from
breast cancer patients who had previously received bone
marrow transplants from male donors. Previous studies have
revealed that ductal lavage samples from breast cancer
patients contain up to thousands of macrophages [26,27].
Bonnie King (Quinnipiac University, Hamden, CT, USA)
presented data showing that large numbers of macrophages
are also present in cytologically benign breast fluids collected
from healthy, asymptomatic women recruited from the general
population. The presence of large numbers of intraductal
macrophages in healthy breast ducts are in keeping with
observations in a mouse model system showing that
macrophages are recruited to and within the growing end
buds of the mammary gland during ductal morphogenesis
[28]. Sanford Barsky ended his talk by stating that
characterization of the crosstalk between the infiltrating cells
and resident breast cells will be critical to our understanding
of mammary gland biology and breast cancer.
The minimally invasive nature of intraductal approaches
permits serial sampling, so that the breast tissue can be
measured as a function of physiologic and intervention
variables. Robert Chatterton (Northwestern University,
Chicago, IL, USA) reported on his studies to evaluate breast
fluids as a method for assessing the hormonal status of the
breast [29,30]. In keeping with other reports [4,31], he
reported that estradiol and progesterone are concentrated up
to 10-fold in NAF relative to serum. Bonnie King presented
immunocytochemical data showing that intraductal
macrophages express aromatase, suggesting a potential
mechanism for the estradiol gradient. Dr Chatterton also
reported that although NAF estradiol levels were stable
during the menstrual cycle and over a period of 15 months in
premenopausal women, they decreased dramatically in
association with exercise and with oral contraceptive usage.
He also showed that estrogen-responsive proteins correlated
with estrogen levels, concluding that hormone concentrations
in NAF are good predictors of the activities.
Many substances associated with the growth, development,
and tumorigenesis of the breast have been detected in breast
fluids. Although some of these substances are secreted by
resident and infiltrating cells, others traverse the ductal
epithelium via transcellular and paracellular pathways. Do
these substances turn over on a regular basis, or does the
intraductal compartment represent a ‘stagnant pond’, potentially
harboring the accumulation of bioactive substances? Fernando
Mannello (University ‘Carlo Bo’, Urbino, Italy) presented his
hypothesis that breast fluid composition is determined largely
by the type of intercellular junctional complexes within the
ductal epithelium [32-34]. In previous work using SDS-PAGE
analysis, he observed two biochemically distinct types of
NAF. Type I NAF, found in healthy control women, had
protein profiles similar to plasma, whereas type II fluid,
observed in a high proportion of breast cancer patients,
resembled breast tumor cytosol extracts. Ultrastructural
analysis has suggested that type I NAF is associated with the
presence of leaky tight junctions, allowing for the unrestricted
movement of substances in and out of the ductal
compartment. Type II NAF is associated with the presence of
tight and gap junctions that seal the ductal epithelium.
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Nick Petrakis suggested that age-related decreases in the
reabsorption of breast fluid may lead to prolonged exposure
of the breast epithelium to chemical substances in NAF that
may lead to breast cancer. Karl Karnaky (Medical University of
South Carolina, Charleston, SC, USA) is studying the
membrane transporter MRP2 (multidrug resistance associa-
ted protein transporter), which is located on the apical
surfaces of exocrine gland epithelial cells and transports a
variety of endogenous and exogenous substances into the
breast ducts [35]. He pointed out that, ‘breast ductules are
the most unusual exocrine glands in the body in that they may
never be flushed’, leading to the potential concentration of
protective as well as deleterious substances within the
luminal compartment of the gland. He is currently studying
the dynamics of transport using cultured breast epithelial
cells, with the goal of unravelling the uptake and regulation of
protective substances such as antioxidants and chemo-
therapeutic agents, as well as deleterious substances such
as steroids and carcinogens.
Pilot grants
The Dr Susan Love Research Foundation used an expedited
grant review mechanism to distribute pilot grants at the
Symposium. Applicants submitted one-page abstracts and
responsive proposals were selected for presentation at the
meeting. A multidisciplinary peer review committee,
composed of basic scientists, breast cancer activists, and
physicians, evaluated the proposals and presentations at the
meeting. This year, 11 researchers presented proposals. At
the close of the Symposium, the Foundation provided a total
of $85,000 to support the pilot work of seven promising
researchers utilizing the intraductal approach for a wide
range of projects.
The 2005 recipients were: Patricia Berg, PhD (George
Washington University Medical Center), ‘Expression of BP1
in ductal lavage samples from women at risk for breast
cancer’; Brian K Petroff, DVM, PhD (University of Kansas
Medical Center), ‘Laser capture microdissection and real time
polymerase chain reaction to assess breast biomarker gene
expression following random periareolar fine needle
aspiration and ductal lavage’; Ferdinando Mannello, PhD
(University ‘Carlo Bo’), ‘Bio-molecular characterization and
cytometric evaluation of nipple aspirate fluids to identify bio-
markers of breast cancer’; Scott L Kominsky, PhD (The Johns
Hopkins University School of Medicine), ‘Intraductal nano-
polymer drug delivery for breast cancer prevention and
therapy’; Regina Brown, MD (The Johns Hopkins University
School of Medicine), ‘The feasibility and safety of intraductal
administration of pegylated liposomal doxorubicin (Doxil) in
women’; Edna K Valdes, MD (Beth Israel Medical Center), ‘Is
persistent nipple aspirate fluid in women on tamoxifen
prognostic for adverse breast events?’; and Gertraud
Maskarinec, MD, PhD (University of Hawaii), ‘Short-term
effects of soy on estrogens and breast cell proliferation in
nipple aspirate fluid’.
Conclusion
The 4th Symposium on the Intraductal Approach to Breast
Cancer revealed an active and growing network of
investigators committed to the development of intraductal
approaches. Although much progress has been made since
the first symposium was held in 1999, this year’s meeting
distilled many new challenges and goals. Progress toward
these goals, along with the results of this year’s pilot grant
projects, will be presented at the 5th Intraductal Symposium
on the Intraductal Approach to Breast Cancer in 2007.
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